Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q3 FY24 results · Oct–Dec 2023
Gufic Biosciences reported revenue from operations of ₹201.78 crore and net profit of ₹22.26 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 201.78 | — | — | 214.87 | −6.1% |
| Other income | 0.42 | — | — | 0.33 | +26.7% |
| Total income | 202.20 | — | — | 215.21 | −6.0% |
| Profit before tax | 29.56 | — | — | 30.95 | −4.5% |
| Net profit for the period | 22.26 | — | — | 23.21 | −4.1% |
| EPS, basic (₹) | 2.23 | — | — | 2.39 | −6.7% |
| Net margin (%) | 11.0 | — | 10.8 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 201.78 | 177.47 | +13.7% | 214.87 | −6.1% |
| Other income | 0.42 | 0.76 | −44.1% | 0.33 | +26.7% |
| Total income | 202.20 | 178.23 | +13.4% | 215.21 | −6.0% |
| Profit before tax | 29.56 | 27.25 | +8.5% | 30.95 | −4.5% |
| Net profit for the period | 22.26 | 20.34 | +9.4% | 23.21 | −4.1% |
| EPS, basic (₹) | 2.23 | 2.10 | +6.2% | 2.39 | −6.7% |
| Net margin (%) | 11.0 | 11.5 | 10.8 |
Consolidated
- Filed with BSE
- 26 Feb 2024, 17:25 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 Feb 2024, 17:25 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE